Alex Zhu
@alexzhuDO
Followers
569
Following
687
Media
20
Statuses
120
SUO fellow @UWurology / Residency @UMuroresidency
Seattle, WA
Joined March 2020
Incredibly proud of @ApoorvDhir! What a huge accomplishment 🔥🔥
🎉 The @AmerUrological and the UCF are excited to recognize 12 researchers as recipients of the 2025 Urology Care Foundation Research Scholar Awards! This program has invested over $30 million to support over 675 Research Scholars! Click to learn more 👉 https://t.co/aWOiuUsPR9
2
3
19
Check out these additional papers https://t.co/ZZlXehrXmT
@DSRoberson93 - data from Mayo of 28pt with EVP + consolidative Cx https://t.co/yHe7zokSuo
dailynews.ascopubs.org
The role of radical cystectomy in the era of enfortumab vedotin plus pembrolizumab (EVP) must be individualized, based on the patient’s response to EVP treatment, and guided by a comprehensive...
1
0
5
@siadaneshmand with additional 💡: -need surveillance cysto after EVP (NCCN only recommends if clinically indicated) -selection for consolidative Cx is key: Cx after EVP is challenging w/ significant democratic reaction + fibrosis (similar to PC-RPLND for seminoma)
1
0
1
@FedGhali argues for potential role of Cx -older cisplatin studies suggest consolidative cx may have role -bladder CA w/ tumor heterogeneity ➡️ bladder may have EVP resistant subclones -consolidative Cx may be over treatment in some, but may offer real benefit in others
1
0
1
Excellent session on role of consolidative therapy following EV-P in metastatic/locally advanced bladder CA #BCANTT25 NCCN recommends role for consolidative therapy “if a complete or partial response is noted following treatment of metastatic disease in select cases”
1
2
9
🙏🏻 to @BladderCancerUS for the JQTF award. And 100x thanks to @PGrivasMDPhD and Jonathan Wright my amazing mentors, for helping me design the TRIFECTA trial. This MIBC trial builds upon the NIAGARA regiment by adding nadofaragene to improve locoregional control. Launching soon!!
Thanks @shilpaonc @MaxKates et al. Fantastic to be at #TT25 @BladderCancerUS excited to partner with stakeholders in our teamwork against #bladdercancer So proud of mentees who received JQTF award: @DRBakaloudiMD @alexzhuDO Congrats to all awardees @AmandaMyersMD @Anto_cigliola
2
6
44
The future of bladder cancer is in great hands. 👏 Stellar class of 2025 John Quale Travel Fellows! @BladderCancerUS #BCANTT25
Congratulations to all the 2025 John Quale Travel Fellows; and especially to our own @MDAndersonNews crew! @AmandaMyersMD @Sood11 Comron Hassanzadeh https://t.co/gY5wmOaQOH
@BladderCancerUS @IBCG_BladderCA #BCANTT25 #OncSurgery
1
16
56
Congratulations to @alexzhuDO and @lisazxy080808! Dr. Zhu presented his research on the impact of arsenic levels on incident urologic cancers in Washington State, while Dr. Zhang discussed post-traumatic stress disorder in adults who underwent childhood voiding cystourethrogram
0
2
30
Great thread by @DrSpratticus on a topic I’ve been asked about by patients many times in the past week
@AmericanCancer @dr_coops @jeshoag @VickersBiostats @AmerUrological @ASCO @ASTRO_org @PCF_Science @wandering_gu @EdwardSchaeffer @NRGonc @Veracyte @Davicioni @JoeBiden @AmarUKishan @theNCI 15/x Summary: - President Biden’s physician followed the current USPSTF recommendation to not perform PSA screening in men >70yo - However, the USPSTF recommendations are flawed as PCa is common in men >70yo, is often more aggressive, if untreated men are more likely to die of
0
0
4
Grateful to have received the SWOG Genitourinary Scholarship. Named in honor of the late Dr. Vogelzang, it selects one early career investigator for longitudinal clinical trial mentorship What an all 💫 group of mentors!! @montypal
@UroCancer
@daniel_hamstra
2
1
59
Always great watching my dear friend present his impactful research. Kristian Stensland (@stensy) at SWOG describing how AI can be used in a different way — to increase enrollment in clinical trials and more easily identify eligible patients
0
0
14
Really important work by @BenPockros
Benjamin Pockros, MD, MBA, (@BenPockros) discusses the potential impact of the Inflation Reduction Act's cap on out-of-pocket costs for Medicare Part D enrollees. @UMichUrology
https://t.co/zxiGDJNgXk
0
0
5
GU Oncology Early Career Thought Leaders Conference A+ lectures about leadership, finding 1st job, clinical trials, time management, public speaking, networking. Stuff we don’t hear at typical meetings 🙏🏻to organizers @zklaassen_md @apolo_andrea + all the amazing speakers!
1
7
46
The @PCFnews GU Oncology Early Career Thought Leaders meeting is a must for early career investigators. Brilliant organization from @apolo_andrea & @zklaassen_md w terrific talks from @AlanBryce9, @ERPlimackMD, @tbivala1, @ArjunBalarMD. Even better has been the discussions with
1
23
75
Applying for a @UroOnc fellowship this year and interested in learning more about the @uwurology SUO Fellowship? We are excited to meet you! Please join us at #SUO2024 on Dec 3 @ 5:30pm to meet with current fellows, faculty, and recent alumni. DM me to RSVP.
0
5
45
Unbelievably proud of these two for matching at their top choice 🥇for SUO @UroOnc Fellowship These guys are awesome clinicians, researchers, coresidents, and have become two of my best friends. CONGRATS! @TrinerDaniel 🌲@StanfordUrology
@ApoorvDhir 🐏 @UNCurology
5
5
66
Congrats to amazing @SteveBlinka @MeeraChappidi for @ASCO YIA & their amazing mentors @HsiehLab @DanLinMD We are proud @uwurology @fredhutch @HutchPresident Steve & Meera: brilliant, kind, hard working! @OncoAlert @JessicaHawleyMD @spsutkaMD @yawnyame @ClaireDlc @RahulBanerjeeMD
Congrats to all the @ASCO #YIA recipients and to Steve Blinka @steveblinka @HsiehLab. Pretty cool to see a trainee take the same steps as the older crusty. @PGrivasMDPhD @JessicaHawleyMD @jklee_lab
4
10
52
Further proof that AS is safe + preferred for favorable risk pCA (cohort: 90% GG1) Authors argue re importance of confirmatory biopsy…23% of pts upgraded at this point But in practice we often avoid confirmatory biopsy for GG1 pCA, esp with negative mpMRI What to do? 😮
Just out in @JAMA_current: Long-term outcomes of prostate cancer AS in PASS. Since 2008: ➡️2,155 patients with median 7.2 year f/u. ➡️21 patients have developed metastatic disease ➡️3 prostate cancer-related deaths https://t.co/QfFvsIJmOi Track each patient 👇
1
1
12
Beaming with joy, pride, and admiration as @samsimsal is awarded the @AmerUrological Gold Cystoscope. He is an absolutely incredible physician, surgeon, scientist, and friend, and seeing him get this amazing recognition is something I’ll never forget.
1
20
144